These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2210 related articles for article (PubMed ID: 30377993)
21. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Jayakumar S; Loomba R Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745 [TBL] [Abstract][Full Text] [Related]
22. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Aron-Wisnewsky J; Warmbrunn MV; Nieuwdorp M; Clément K Gastroenterology; 2020 May; 158(7):1881-1898. PubMed ID: 32044317 [TBL] [Abstract][Full Text] [Related]
23. Targeting Dysbiosis for the Treatment of Liver Disease. Anand G; Zarrinpar A; Loomba R Semin Liver Dis; 2016 Feb; 36(1):37-47. PubMed ID: 26870931 [TBL] [Abstract][Full Text] [Related]
24. GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN MANAGEMENT OF OBESITY AND PREDIABETES: REVIEW OF RANDOMIZED CONTROLLED TRIALS. Barengolts E Endocr Pract; 2016 Oct; 22(10):1224-1234. PubMed ID: 27409822 [TBL] [Abstract][Full Text] [Related]
25. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079 [TBL] [Abstract][Full Text] [Related]
26. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436 [TBL] [Abstract][Full Text] [Related]
27. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies. Jayachandran M; Qu S Rev Endocr Metab Disord; 2023 Dec; 24(6):1189-1204. PubMed ID: 37840104 [TBL] [Abstract][Full Text] [Related]
28. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation]. Aitbaev KA; Murkamilov IT; Fomin VV Ter Arkh; 2017; 89(8):120-128. PubMed ID: 28914862 [TBL] [Abstract][Full Text] [Related]
29. The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review. Vakilpour A; Amini-Salehi E; Soltani Moghadam A; Keivanlou MH; Letafatkar N; Habibi A; Hashemi M; Eslami N; Zare R; Norouzi N; Delam H; Joukar F; Mansour-Ghanaei F; Hassanipour S; Samethadka Nayak S Nutr Diabetes; 2024 May; 14(1):25. PubMed ID: 38729941 [TBL] [Abstract][Full Text] [Related]
30. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205 [TBL] [Abstract][Full Text] [Related]
31. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Hartmann P; Schnabl B Semin Liver Dis; 2021 Jan; 41(1):87-102. PubMed ID: 33957682 [TBL] [Abstract][Full Text] [Related]
32. Anti-inflammatory effects of probiotics and synbiotics on patients with non-alcoholic fatty liver disease: An umbrella study on meta-analyses. Mahapatro A; Bawna F; Kumar V; Daryagasht AA; Gupta S; Raghuma N; Moghdam SS; Kolla A; Mahapatra SS; Sattari N; Amini-Salehi E; Nayak SS Clin Nutr ESPEN; 2023 Oct; 57():475-486. PubMed ID: 37739694 [TBL] [Abstract][Full Text] [Related]
33. Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies. Koning M; Herrema H; Nieuwdorp M; Meijnikman AS Gut Microbes; 2023; 15(1):2226922. PubMed ID: 37610978 [TBL] [Abstract][Full Text] [Related]
34. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice. Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483 [TBL] [Abstract][Full Text] [Related]
35. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. Bakhshimoghaddam F; Alizadeh M Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514 [TBL] [Abstract][Full Text] [Related]
36. The Gut Microbiota and Nonalcoholic Fatty Liver Disease. Quigley EM; Monsour HP Semin Liver Dis; 2015 Aug; 35(3):262-9. PubMed ID: 26378643 [TBL] [Abstract][Full Text] [Related]
37. The synbiotic combination of probiotics and inulin improves NAFLD though modulating gut microbiota. Zhang C; Fang T; Shi L; Wang Y; Deng X; Wang J; Zhou Y J Nutr Biochem; 2024 Mar; 125():109546. PubMed ID: 38072206 [TBL] [Abstract][Full Text] [Related]
38. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Meroni M; Longo M; Dongiovanni P Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910 [TBL] [Abstract][Full Text] [Related]
39. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. Milosevic I; Vujovic A; Barac A; Djelic M; Korac M; Radovanovic Spurnic A; Gmizic I; Stevanovic O; Djordjevic V; Lekic N; Russo E; Amedei A Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658519 [TBL] [Abstract][Full Text] [Related]
40. Microbiota on biotics: probiotics, prebiotics, and synbiotics to optimize growth and metabolism. Edwards PT; Kashyap PC; Preidis GA Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G382-G390. PubMed ID: 32755308 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]